ArticleMedComm2026
IgA Antibodies Reveal Covert Infection With Mpox Virus in People Living With HIV in the Community: A Prospective Longitudinal Cohort Survey.
Article in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Covert mpox virus (MPXV) infection among people living with HIV (PLWH) remains poorly understood. This study aimed to investigate undetected MPXV infections through seroepidemiological analysis. We recruited 148 PLWH during July 2-9, 2023 (baseline), with 60 and 148 participants returning for 4- and 14-month follow-ups, respectively. PCR testing showed that all saliva and blood samples were negative for MPXV-DNA. The titers of IgG, IgA, and IgM were evaluated using ELISA with virions. MPXV-IgA and IgM were undetectable, 15 participants born before 1980 had low MPXV-IgG at baseline. At 14 months, 10 participants (6.8%) showed increased MPXV-IgG titers. All seroconverters had detectable neutralizing antibodies, and nine were MPXV-IgA positive. Further results showed that IgG seropositivity against MPXV proteins (A29L, A35R, B6R, E8L, H3L, and M1R) ranged from 0% to 80%, while IgA seropositivity ranged from 0% to 60% among the 10 participants at the 14-month. The B6R and E8L combination showed IgG detection comparable to whole virions, while E8L and H3L combination increased IgA seropositivity to 70%. The occurrence of MPXV covert infection among PLWH underscores the need to improve surveillance strategies in the community. The presence of MPXV-IgA in blood may offer a preliminary temporal signal of MPXV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.